We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Weekly Paclitaxel Is Effective in Advanced Breast Cancer Study

Feb 1, 1998
Volume: 
7
Issue: 
2
  • Breast Cancer

SAN ANTONIO—A weekly outpatient paclitaxel (Taxol) regimen led to rapid responses in more than 40% of a group of heavily pretreated women with metastatic breast cancer, said Dr. Hans-Joachim Luck, of the Medical University of Hannover, Germany. [See page 30 for a commentary on single-agent taxanes in this setting.]

After 6 weeks of treatment, 15 of 41 evaluable patients had a partial response, and four others had a minor objective response. An additional 18 patients had disease stabilization. Duration of response exceeded 300 days.

“These results show that a weekly paclitaxel schedule is feasible in the outpatient setting and leads to a substantial response rate in heavily pretreated patients,” Dr. Luck said at a poster presentation at the 20th Annual San Antonio Breast Cancer Symposium. “The weekly regimen induced a remarkable time to progression.”

The findings confirm previous evidence of high activity with weekly paclitaxel in heavily pretreated patients presented last year at the American Society of Clinical Oncology meeting (Proc Am Soc Clin Oncol 16:597, 1997), he added.

Typically, paclitaxel regimens entail a 3-hour infusion every 3 weeks. Shorter, more frequent infusions might be more comfortable and convenient for patients treated in the outpatient setting, he said.

The Hannover investigators evaluated a weekly regimen in 53 patients with advanced metastatic breast cancer. About 80% of patients had two or more metastatic sites. Half had been treated previously with anthracyclines, and 30% had previously received taxane-based therapy. Ten had received combination therapy with an anthracycline and a taxane.

The weekly regimen included paclitaxel dosages that ranged from 60 to 90 mg/m2, infused over an hour. Twelve patients received the lowest dose, eight received 70 mg/m2, and 30 received 90 mg/m2. Premedication consisted of dexamethasone, clemastine and raniti-dine. Patients completed a median of 12 weekly cycles (range, 1 to 21).

In addition to the partial and minor responses achieved after 6 weeks, 18 patients had stable disease. At 12 weeks, 10 evaluable patients had a partial response, 3 had a minor response, and 7 had stable disease.

Among responding patients, the median duration of response was 320 days. In patients with disease stabilization, duration of status was 300 days. Prolonged responses also were seen in patients who had a history of anthracycline therapy (312 days) or taxane therapy (262 days).

The regimen was associated with a favorable toxicity profile, Dr. Luck said. No patient developed grade 3-4 neutro-penia, anemia, thrombocytopenia, or febrile neutropenia. With respect to non-hematologic toxicity, 60% of patients had alopecia. The regimen caused no nausea, vomiting, mucositis, or grade 3-4 neuropathy. Grade 2 neuropathy occurred in 15% of the patient population.

“The overall quality of life was improved in patients, compared to the 3-hour infusion,” Dr. Luck said. “In particular, patients who had bone metastases reported decreased bone pain and a reduced use of analgesics.”

The response rates are at least comparable to those observed in early paclitaxel clinical trials in similar populations of heavily pretreated breast cancer patients, he added. Those early trials employed a 3-hour infusion, which was associated with increased toxicity.

“The toxicity may be dependent on the peak drug level,” Dr. Luck said. “We observed no severe neutropenia with the 1-hour paclitaxel schedule, but grade 3-4 neutropenia is very common with a 3-hour, 3-week schedule.”

Related Articles

  • Prognostic Tool Can Guide Extended Endocrine Therapy in ER+ Breast Cancer
  • Forecasting PARP Inhibitor Resistance in Breast Cancer Patients
  • OncoMasTR Assay May Help Some Breast Cancer Patients Avoid Chemo
  • RAD51 Linked With PARP Inhibitor Resistance in BRCA-Mutated Breast Cancer
  • HER2+ Breast Cancer Subtypes Resistant to TKIs Through Differing Mechanisms

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.